QuartrQuartr

TORNTPHARM: Revenue and EBITDA surged; integration synergies support a gradual recovery and margin gains

Moins d'1 minute de lecture

Q2 revenue rose 51% and operating EBITDA rose 54%, while integration temporarily affected JB’s international sales. Cost synergies are ahead of plan, and management expects improving H2 margins and a gradual recovery in JB growth.

Based on Torrent Pharmaceuticals Ltd [TORNTPHARM] Q2 26/27 Audio Transcript — Oct. 23 2026

Clause de non-responsabilité